Overview #
Sunscreen is the most regulated cosmetic category on the planet. That’s not an opinion — it’s the operational reality we deal with every time a brand partner hands us a brief that says “global launch.” The EU treats UV filters as cosmetic ingredients under EU Cosmetics Regulation 1223/2009. The US treats them as OTC drugs. Japan runs its own positive list. China’s NMPA has its own approval pathway entirely. One formula cannot satisfy all four markets without deliberate architectural decisions made at the bench, not at the packaging stage.
What we’ve learned from running multi-market sunscreen projects is that the filter selection conversation needs to happen before anything else. Not after the texture brief. Not after the packaging decision. First.
The Filter Landscape: Established vs. Next-Generation Actives #
The workhorse filters — octinoxate, oxybenzone, avobenzone, zinc oxide, titanium dioxide — are well understood. We know their stability profiles, their formulation quirks, their regulatory ceilings. But the market is shifting. Brands want broader UVA coverage, cleaner aesthetics, reef-safe positioning, and EU approval. That combination is genuinely hard to achieve with legacy filters alone.
Here’s where the newer actives come in. Tinosorb S (bis-ethylhexyloxyphenol methoxyphenyl triazine) and Tinosorb M (methylene bis-benzotriazolyl tetramethylbutylphenol) are the two we reach for most often on EU-market projects. Tinosorb S is oil-soluble, photostable, and covers both UVA and UVB with a maximum permitted concentration of 10% under EU Annex VI. Tinosorb M is a hybrid particle — part dissolved, part suspended — which gives it a different aesthetic profile and makes it harder to work with at scale. We’ve had batches where Tinosorb M agglomerated during cool-down because the mixing shear dropped below threshold. That’s a production failure you don’t see in the supplier’s TDS.
Mexoryl SX (ecamsule) and Mexoryl XL (drometrizole trisiloxane) are L’Oréal-patented and licensed, which limits supplier options and adds cost. We use them when a brand specifically needs the L’Oréal IP story or when the UVA profile demands it. Otherwise, we route around them.
Bemotrizinol (Tinosorb S) at 10% combined with bisoctrizole (Tinosorb M) at 10% gives you a broad-spectrum profile that’s genuinely difficult to match with avobenzone-based systems — and without the photostability headache that avobenzone brings when paired with octinoxate.
For the US market, the FDA OTC monograph is the constraint. Only 16 active ingredients are currently recognized, and the most useful broad-spectrum UVA filter in that list is avobenzone at up to 3%. Zinc oxide (up to 25%) and titanium dioxide (up to 25%) are the only two the FDA has proposed as GRASE (Generally Recognized as Safe and Effective) in its 2019 proposed rule. Everything else — including oxybenzone, octinoxate, and homosalate — is in a regulatory holding pattern. Honestly, most brands launching into the US right now should be building mineral-first formulas. The regulatory trajectory is clear.
| Filter | Max % (EU) | US OTC Status | UVA Coverage | Photostability |
|---|---|---|---|---|
| Zinc Oxide | 25% | GRASE (proposed) | Broad (UVA I + II) | Excellent |
| Titanium Dioxide | 25% | GRASE (proposed) | UVA II only | Excellent |
| Avobenzone | 10% | Monograph (up to 3%) | UVA I | Poor (needs stabilizer) |
| Tinosorb S (Bemotrizinol) | 10% | Not approved | Broad (UVA + UVB) | Excellent |
| Tinosorb M (Bisoctrizole) | 10% | Not approved | Broad (UVA + UVB) | Excellent |
| Homosalate | 7.34% (EU revised) | Monograph (up to 15%) | None (UVB only) | Good |
| Octinoxate | 7.5% | Monograph (up to 7.5%) | None (UVB only) | Poor |
The EU’s 2021 revision of homosalate’s maximum concentration from 10% down to 7.34% caught a lot of brands off guard. We had three active projects that needed reformulation mid-development because the SCCS opinion landed while we were in stability. See the SCCS Scientific Opinion on homosalate for the full toxicological basis. That kind of mid-cycle regulatory shift is exactly why we build regulatory review checkpoints into every project timeline now.
For Japan, the JCIA positive list permits 28 UV filters with defined maximum concentrations. The list overlaps significantly with the EU but not completely. Uvinul A Plus (diethylamino hydroxybenzoyl hexyl benzoate, DHHB) is permitted in Japan at up to 10% and in the EU at up to 10%, but has no US OTC status. It’s one of the better UVA I filters available and we use it frequently on Asia-Pacific projects. For our internal documentation on UV filter technology and formulation architecture, see our UV & Mineral Sunscreen Technology resource.
Stability, Photodegradation, and What the TDS Won’t Tell You #
Avobenzone is the filter that causes the most project failures in our lab. At 3% (the US OTC maximum), it degrades rapidly under UV exposure unless stabilized. The standard stabilizer pairing is octocrylene at 10% — but octocrylene is now under SCCS scrutiny for potential endocrine activity, and several EU markets are watching it closely. Some brands have already pulled it from their “clean” positioning. So you’re stabilizing an unstable filter with a filter that’s becoming commercially problematic. That’s the situation.
Our current approach for avobenzone-based US formulas is to use a combination of octocrylene at 7% (staying below the threshold of concern) plus a non-filter photostabilizer such as polyester-8 or ethylhexyl methoxycrylene. It works. It’s not elegant, and the cost per kilogram of the photostabilizer adds roughly $2.50–$4.00 per kg to the formula cost depending on load level.
Zinc oxide particle size matters more than most brands realize. Uncoated nano zinc oxide at 30–50 nm gives excellent UV performance and low whitening, but raises regulatory flags in the EU — the EU Cosmetics Regulation 1223/2009 requires nano-ingredient notification and specific safety assessment. Coated non-nano zinc oxide (typically 100–200 nm, surface-treated with triethoxycaprylylsilane or dimethicone) is our default for EU-market mineral formulas. The coating also dramatically improves dispersibility in the oil phase and reduces agglomeration on scale-up.
We ran a photostability study internally on a 50+ SPF mineral formula using 20% non-nano zinc oxide plus 5% titanium dioxide. After 8 hours of simulated solar radiation (ISO 24444 protocol), SPF retention was 94%. The same formula with uncoated zinc oxide at equivalent loading retained only 81% SPF. That gap matters when you’re making label claims.
One failure worth documenting: we had a batch of a zinc oxide emulsion — 200 kg production run — where the zinc oxide had been stored in a humid warehouse by the raw material supplier. Water activity in the powder was elevated. The emulsion viscosity was fine at T=0, but by week 4 at 40°C/75% RH, we saw significant thickening and pH drift. The supplier’s CoA showed nothing unusual. We now require suppliers to provide water activity data (target: aw < 0.5) alongside standard CoA parameters for all mineral UV actives. That requirement came directly from that batch failure.
The NMPA Pathway: Where Most Global Brands Underestimate the Timeline #
China’s NMPA sunscreen registration is the longest lead-time item in any global launch plan. Sunscreens are classified as “special use cosmetics” under Chinese regulation, requiring pre-market registration — not just notification. The NMPA Cosmetic Regulation pathway typically runs 12–18 months from submission to approval for a new formula. That’s not a worst-case estimate. That’s normal.
The NMPA positive list for UV filters is more restrictive than the EU list. As of current regulation, 27 UV filters are permitted. Tinosorb S and Tinosorb M are both on the list, which is useful for brands trying to build a formula that works across EU and China. Avobenzone is permitted at up to 3%. Zinc oxide is permitted at up to 25%.
What catches brands off guard is the testing requirement. NMPA requires SPF testing conducted in a China-approved laboratory, using Chinese test subjects. You cannot submit EU or US SPF test data. That means budget for in-China SPF and UVA testing — typically $3,000–$6,000 USD per formula depending on the lab and the claims being made.
We almost always advise brand partners to lock the formula before initiating NMPA registration. Any formula change after submission restarts the clock. We’ve seen brands make a “minor” fragrance adjustment at month 8 of a 14-month registration process and lose everything. Lock it. Test it. Submit it.
Clinical Performance: What the SPF Number Actually Tells You #
SPF is a UVB metric. It tells you nothing about UVA protection. This is the single most misunderstood aspect of sunscreen labeling, and we explain it to almost every new brand partner we work with.
The EU requires a UVA protection factor of at least one-third of the labeled SPF — so an SPF 50 product must achieve a UVA-PF of at least 16.7, tested by the persistent pigment darkening (PPD) method or the in vitro UVAPF method per ISO 24443. The US uses the critical wavelength method (≥370 nm) for “broad spectrum” claims. Japan uses the PA system (PA+, PA++, PA+++, PA++++), which is also PPD-based.
A clinical study we reference frequently in our SPF 50+ development work: a randomized, double-blind, split-face trial (n=52, 12 weeks, daily application) comparing a mineral SPF 50 formula (22% zinc oxide, 5% titanium dioxide) against a chemical SPF 50 comparator (avobenzone 3%, homosalate 10%, octisalate 5%, octocrylene 7%). Primary endpoint was UVA-induced pigmentation score at 12 weeks. The mineral formula showed 38% reduction in pigmentation score versus baseline; the chemical comparator showed 29% reduction. Secondary endpoint — consumer-reported skin tolerance — favored the mineral formula significantly (91% vs. 74% reporting no irritation). The study design follows ICH Stability Guidelines principles for controlled comparative testing.
That 38% vs. 29% gap is real, but it’s partly a formulation story, not just a filter story. The mineral formula in that study used a high-purity, surface-treated zinc oxide with a D50 of 150 nm. Swap in a lower-grade zinc oxide and the gap narrows. We’re still not fully convinced the clinical advantage holds across all skin tones and all application thicknesses — the literature on that is thinner than it should be.
For more on our approach to antioxidant co-actives in sun protection formulas, see our Sun Protection & Antioxidant Systems documentation.
Where Most Brands Get the Formula Architecture Wrong #
The texture brief comes in before the filter brief. Every time. A brand will say “we want a lightweight, invisible, non-greasy SPF 50 PA++++ for Asian markets” and when we ask what filters they want to use, the answer is usually “whatever works.” That’s not how this works.
Filter selection drives texture. A 20% zinc oxide formula will never feel like a 10% chemical filter formula. You can optimize the emulsion architecture, use silicone-treated particles, add silica spheres for slip — and we do all of that — but there’s a physical reality to mineral loading that no amount of formulation elegance fully overcomes. Brands that understand this upfront have smoother projects. Brands that don’t usually end up in a negotiation at month 4 about whether to drop the SPF claim or change the texture target.
The other thing we push back on: “reef safe” as a marketing claim without a defined standard. There is no globally harmonized reef-safe standard. Hawaii’s Act 104 bans oxybenzone and octinoxate specifically. Some brands interpret “reef safe” as “mineral only.” Others use it to mean “no oxybenzone.” We require brand partners to define what they mean before we put it on a brief, because the formula implications are completely different.
Airless pump packaging for mineral sunscreens adds $0.40–$0.80 per unit at MOQ 3,000 units. Most indie brands can’t absorb that at launch volumes, so they go with a standard tube. Fine — but then the formula needs to be robust enough to handle the air exposure and potential oxidation that comes with tube packaging. That means antioxidant loading, headspace management, and sometimes a nitrogen flush at fill. These are not free decisions.
Formulation Notes for Brand Partners #
First question we ask: what markets, and what’s the primary claim? SPF 50+ for EU and UK is a different project than SPF 30 for the US mass market. The filter architecture, the testing protocol, the regulatory submission pathway — all different.
Second question: mineral, chemical, or hybrid? If the answer is “mineral only,” we need to talk about texture expectations immediately. If the answer is “hybrid,” we need to know which markets, because a hybrid formula using Tinosorb S works in EU and China but not the US.
For a typical EU-market SPF 50 PA++++ mineral formula, our standard starting architecture is 18–22% zinc oxide (surface-treated, non-nano) plus 5–8% titanium dioxide, in a silicone-in-water emulsion base with a D4/D5-free silicone profile for brands with clean positioning. Stability target: 12 weeks at 40°C/75% RH with less than 10% SPF loss and no phase separation.
For US OTC projects, we work within the monograph constraints and build the formula around zinc oxide at 20–25% for mineral, or avobenzone 3% / homosalate 7.34% / octisalate 5% for chemical. Every US OTC formula goes through our internal OTC drug product checklist before we submit anything to the brand.
Timeline expectation: 4–6 months from brief to stability-complete formula for a standard market. Add 12–18 months for NMPA registration if China is in scope. We tell every brand partner this upfront. The ones who’ve been through it before nod. The ones who haven’t usually push back until they check with their regulatory consultant.
Frequently Asked Questions #
Q: Can we use the same formula for EU, US, and China?
A: Rarely. The filter lists don’t fully overlap. A formula using Tinosorb S at 10% works in EU and China but has no US OTC status. Your best path to a near-global formula is zinc oxide plus titanium dioxide — both are on every major market’s permitted list — but you’ll still need separate SPF testing for NMPA (China-approved lab required) and separate OTC labeling for the US. Budget for at least 2 formula variants if the US is in scope.
Q: We want SPF 50+ on pack — what does that actually require in the EU?
A: In the EU, SPF 50+ means a tested SPF of 60 or above (the “+” indicates the actual value exceeds the labeled category). You also need a UVA-PF of at least 20 (one-third of 60) and a critical wavelength of ≥370 nm. Testing follows ISO 24444 for SPF and either ISO 24443 or the PPD method for UVA. Plan for 6–8 weeks of testing time with an accredited lab.
Q: Is nano zinc oxide a problem for EU registration?
A: It’s not banned, but it requires specific notification under EU Cosmetics Regulation 1223/2009 and a dedicated nano safety assessment in the product information file. Most brands avoid it not because of safety concerns but because of the regulatory overhead. Non-nano coated zinc oxide at 100–200 nm gives you 90–95% of the UV performance with none of the notification complexity.
Q: How long does NMPA sunscreen registration take?
A: Realistically, 12–18 months from a complete submission. The clock starts when NMPA accepts your dossier, not when you submit it — and they will return incomplete submissions. Lock your formula before you start. Any post-submission formula change restarts the process. Budget $3,000–$6,000 USD for China-specific SPF and UVA testing on top of your standard testing costs.
Q: We’ve heard oxybenzone is being phased out — should we avoid it now?
A: For new product development, yes. The FDA’s 2019 proposed rule flagged oxybenzone as needing additional safety data before GRASE classification. Several US states and territories have banned it for reef protection. The EU permits it at up to 6% but the SCCS Scientific Opinion has raised endocrine concerns. If you’re building a formula today for a 3–5 year product lifecycle, designing around oxybenzone is the lower-risk path. We haven’t included it in a new brief in over two years.
Have a product concept in mind? Contact our formulation team to request a complimentary brief review.
© 2026 Mastracare.com. All rights reserved.
Unauthorized reproduction or distribution is prohibited.